A Randomized, Multi-center, Double-Blind, Controlled, Parallel Design, Phase II Study to Evaluate the Efficacy and Safety Administration by Doses of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension
Latest Information Update: 06 Feb 2026
At a glance
- Drugs BR 1400 (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Boryung Pharmaceutical
Most Recent Events
- 06 Feb 2026 New trial record